Update shared on01 Aug 2025
Fair value Decreased 20%Despite a modest improvement in revenue growth expectations and a lower future P/E ratio indicating a cheaper valuation, analysts have significantly lowered their price target for Community Health Systems from $4.36 to $3.64.
What's in the News
- Issued full-year 2025 earnings guidance, projecting net operating revenues of $12.3–$12.6 billion and a net loss per diluted share of $0.40–$0.10.
- Tim Hingtgen will retire as CEO effective September 30, 2025, and is expected to continue as a consultant.
- Kevin Hammons, currently president and CFO, will become interim CEO following Hingtgen’s retirement; Jason K. Johnson will serve as interim CFO.
- Stockholders approved an amendment to the company’s Restated Certificate of Incorporation.
Valuation Changes
Summary of Valuation Changes for Community Health Systems
- The Consensus Analyst Price Target has significantly fallen from $4.36 to $3.64.
- The Future P/E for Community Health Systems has significantly fallen from 1.39x to 1.11x.
- The Consensus Revenue Growth forecasts for Community Health Systems has significantly risen from 1.3% per annum to 1.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.